PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations [Video]

Whilst many first generation PARP inhibitors are indicated for various cancers, they target PARP1 and 2, despite only PARP1 being the main driver of tumor growth. Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of results from the Phase I/IIa PETRA trial (NCT04644068) of saruparib, a novel PARP1 inhibitor, in patients with breast, ovarian, prostate, or pancreatic cancer with BRCA1/2, PALB2 or RAD51C/D mutations. Saruparib had a promising pharmacodynamic and pharmacokinetic profile, and dose escalation of saruparib proved to be safe and tolerable. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.